69.50
+3.00
+(4.51%)
At close: January 31 at 1:02:06 PM GMT+1
Research Analysis
Earnings Estimate
Currency in USD | Current Qtr. (Jan 2025) | Next Qtr. (Apr 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | -- | -- | -- | -- |
Avg. Estimate | 0 | 0 | 0 | 0 |
Low Estimate | 0 | 0 | 0 | 0 |
High Estimate | 0 | 0 | 0 | 0 |
Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
Currency in USD | Current Qtr. (Jan 2025) | Next Qtr. (Apr 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
No. of Analysts | 25 | 23 | 28 | 28 |
Avg. Estimate | 206.48M | 212.44M | 754.11M | 942.05M |
Low Estimate | 205.4M | 207.46M | 753M | 909.12M |
High Estimate | 214.79M | 218.91M | 762.61M | 1.02B |
Year Ago Sales | 163.78M | 169.19M | 579.91M | 754.11M |
Sales Growth (year/est) | 26.07% | 25.57% | 30.04% | 24.92% |
EPS Trend
Currency in USD | Current Qtr. (Jan 2025) | Next Qtr. (Apr 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Current Estimate | 0 | 0 | 0 | 0 |
7 Days Ago | 0 | 0 | 0 | 0 |
30 Days Ago | 0 | 0 | 0 | 0 |
60 Days Ago | 0 | 0 | 0 | 0 |
90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
Currency in USD | Current Qtr. (Jan 2025) | Next Qtr. (Apr 2025) | Current Year (2025) | Next Year (2026) |
---|---|---|---|---|
Up Last 7 Days | -- | -- | -- | -- |
Up Last 30 Days | -- | -- | -- | -- |
Down Last 7 Days | -- | -- | -- | -- |
Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
Current Qtr. | Next Qtr. | Current Year | Next Year | |
---|---|---|---|---|
8K2.SG | -- | -- | -- | -- |
S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
Maintains | Macquarie: Outperform to Outperform | 1/15/2025 |
Reiterates | Needham: Buy to Buy | 1/7/2025 |
Initiated | Macquarie: Outperform | 12/12/2024 |
Maintains | Mizuho: Outperform to Outperform | 12/9/2024 |
Maintains | Barclays: Equal-Weight to Equal-Weight | 12/9/2024 |
Maintains | Scotiabank: Sector Outperform to Sector Outperform | 12/6/2024 |